<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04832724</url>
  </required_header>
  <id_info>
    <org_study_id>RGX-314-2103</org_study_id>
    <nct_id>NCT04832724</nct_id>
  </id_info>
  <brief_title>RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)</brief_title>
  <official_title>A Phase 2, Open-label Study to Explore the Pharmacodynamics of Two Doses in Two Formulations of RGX-314 Gene Therapy Administered Via Subretinal Delivery in Participants With Neovascular Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regenxbio Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regenxbio Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular&#xD;
      (wet) age-related macular degeneration (nAMD) also referred to as Wet AMD. Wet AMD is&#xD;
      characterized by loss of vision due to new, leaky blood vessel formation in the retina. The&#xD;
      purpose of this phase 2, open label study is to evaluate whether different doses of RGX-314&#xD;
      from two different formulations (clinical versus eventual commercial formulation) perform the&#xD;
      same in humans when delivered by subretinal administration&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up&#xD;
      to 2 million people living with wet AMD in these geographies alone. Current anti-VEGF&#xD;
      therapies have significantly changed the landscape for treatment of wet AMD, becoming the&#xD;
      standard of care due to their ability to prevent progression of vision loss in the majority&#xD;
      of patients. These therapies, however, require life-long repeated intraocular injections to&#xD;
      maintain efficacy. Due to the burden of treatment, patients often experience a decline in&#xD;
      vision with reduced frequency of treatment over time. RGX-314 is being developed as a&#xD;
      potential one-time treatment for wet AMD. RGX-314 uses an AAV8 vector that contains a gene&#xD;
      that encodes for a monoclonal antibody fragment which binds to and neutralizes VEGF activity.&#xD;
      This phase 2, open label study will explore the pharmacodynamics of two doses in two&#xD;
      formulations of RGX-314 gene therapy via subretinal delivery in patients with neovascular&#xD;
      Age-related Macular Degeneration. Approximately 60 patients (15 per cohort) who meet the&#xD;
      inclusion/exclusion criteria will be enrolled in 4 sequential dose cohorts. A dose cohort&#xD;
      will be comprised of 1 of 2 doses of RGX-314 in 1 of 2 formulations in order to explore the&#xD;
      pharmacodynamics of RGX-314 based on aqueous humor transgene product (TP) concentrations. If&#xD;
      the participants meet the study criteria and choose to participate in the study, their&#xD;
      participation in the study will last about 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RGX-314 target protein concentration in aqueous humor</measure>
    <time_frame>At Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of ocular Adverse Events (AEs) and overall AEs</measure>
    <time_frame>Through Week 48</time_frame>
    <description>Evaluate the safety and tolerability of RGX-314</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>At Week 24 and 48</time_frame>
    <description>BCVA measured by Early Treatment Diabetic Retinopathy Study (ETDRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Central Retinal Thickness (CRT)</measure>
    <time_frame>At Week 24 and 48</time_frame>
    <description>CRT is measured by spectral domain optical coherence tomography (SD-OCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Supplemental anti-VEGF injection annualized rate through week 24 and week 48</measure>
    <time_frame>Through Week 24 and week 48</time_frame>
    <description>To assess the need for supplemental anti-VEGF therapy over 48 weeks</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <condition>Wet Macular Degeneration</condition>
  <condition>Wet Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Commercial Formulation Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 of RGX-314</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clinical Formulation Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 of RGX-314</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Commercial Formulation Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 of RGX-314</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clinical Formulation Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 of RGX-314</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RGX-314</intervention_name>
    <description>RGX-314 is a recombinant adeno-associated virus gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein</description>
    <arm_group_label>Clinical Formulation Dose 1</arm_group_label>
    <arm_group_label>Clinical Formulation Dose 2</arm_group_label>
    <arm_group_label>Commercial Formulation Dose 1</arm_group_label>
    <arm_group_label>Commercial Formulation Dose 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females, aged ≥ 50 years and ≤ 89 years.&#xD;
&#xD;
          2. An Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA-letter score between ≤ 78&#xD;
             and ≥ 40 in the study eye at Screening.&#xD;
&#xD;
          3. Diagnosis of choroidal neovascularization (CNV) secondary to age-related macular&#xD;
             degeneration in the study eye previously treated with anti-VEGF.&#xD;
&#xD;
          4. Participants must have demonstrated a meaningful response to anti-VEGF therapy at&#xD;
             study entry.&#xD;
&#xD;
          5. Willing and able to provide written, signed informed consent for this study.&#xD;
&#xD;
          6. Must be pseudophakic (at least 12 weeks postcataract surgery) in the study eye.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. CNV or macular edema in the study eye secondary to any causes other than AMD.&#xD;
&#xD;
          2. Subfoveal fibrosis or atrophy in study eye.&#xD;
&#xD;
          3. Any condition in the investigator's opinion that could limit visual acuity improvement&#xD;
             in the study eye.&#xD;
&#xD;
          4. Active or history of retinal detachment or retinal tear in the study eye.&#xD;
&#xD;
          5. Advanced glaucoma in the study eye.&#xD;
&#xD;
          6. Prior treatment with gene therapy.&#xD;
&#xD;
          7. Myocardial infarction, cerebrovascular accident, or transient ischemic attack within&#xD;
             the past 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patient Advocacy</last_name>
    <phone>1-866-860-0117</phone>
    <email>patientadvocacy@regenxbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix location</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>San Diego location</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Santa Barbara location</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Santa Maria location</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg Location</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baltimore location</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston location</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Reno location</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Albuquerque location</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Philadelphia location</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memphis location</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dallas Location</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Woodlands location</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>wet AMD</keyword>
  <keyword>wAMD</keyword>
  <keyword>neovascular AMD</keyword>
  <keyword>nAMD</keyword>
  <keyword>gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

